Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.

Authors

Jonathan I. Silverberg, George Washington University
Gil Yosipovitch
Eric L. Simpson
Brian S. Kim
Jashin J. Wu
Laurent Eckert
Isabelle Guillemin
Zhen Chen
Marius Ardeleanu
Ashish Bansal
Mandeep Kaur
Ana B. Rossi
Neil M H Graham
Naimish Patel
Abhijit Gadkari

Document Type

Journal Article

Publication Date

3-3-2020

Journal

Journal of the American Academy of Dermatology

DOI

10.1016/j.jaad.2020.02.060

Comments

Online ahead of print

APA Citation

Silverberg, J. I., Yosipovitch, G., Simpson, E. L., Kim, B. S., Wu, J. J., Eckert, L., Guillemin, I., Chen, Z., Ardeleanu, M., Bansal, A., Kaur, M., Rossi, A. B., Graham, N. M., Patel, N., & Gadkari, A. (2020). Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.. Journal of the American Academy of Dermatology, (). http://dx.doi.org/10.1016/j.jaad.2020.02.060

Peer Reviewed

1